Earnings call · Apr–Jun 2026
Symbiotec Pharmalab Limited
Symbiotec Pharmalab reported Apr–Jun 2026 consolidated revenue of ₹218 crore (7% growth from a year earlier) with API business at ₹215 crore & gross margins above 60%. Management targets 20-25% revenue & EBITDA growth for FY27, with new CDMO & complex injectables businesses expected to generate multi-million dollar milestone revenues in Oct 2026 to Mar 2027.
The full notes: the guidance, numbers & KPIs, strategy, outlook, risks, what analysts asked.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
From the company
- Gourav Bhama
- Anil SatwaniChairman and Managingdirectormr. Raghavender Ramachandran
- Raghavender R.
- Saion Mukherjee
- Saion Mukerjee
- Anubhav Sahu
Questions came from
- Tushar ManudhaneMotilal Oswal Financial Services
- Harith AhamedAvendus Spark
- Sagar TannaAlchemie Ventures
- Kartick BaneBajaj Life
- RaajArjav Partners
- Rohan KampaniJM Financial
Topics in this call
Opening remarks
Gourav Bhama
Thank you, Alaric. Thank you. Good evening, everyone. Good morning, everyone. On behalf of JM Financials, I welcome you all to Q1 FY27 earnings call of Symbiotec Pharmalab Limited. We are pleased to have with us management represented by Mr. Anil Satwani, Chairman and Managing Director, and Mr. Raghavender Ramachandran, Chief Financial Officer. We will have opening remarks from the management, followed by a Q&A session. Thank you, and over to you, Mr. Anil, sir.
Read the whole call: 126 paragraphs, 6 analysts' questions with every answer, 6 marked passages.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript as the company filed it on BSE. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.